COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network
COEPTIS (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network and Arketyp Valu, a developer within the Verus Project ecosystem. The collaboration aims to integrate NexGenAI's digital marketing solutions into the upcoming ValuSocial platform, leveraging Verus Coin's blockchain technology and Public Blockchains as a Service (PBaaS).
The Verus Project, which has recently achieved a market capitalization exceeding $500 million, will provide the foundation for ValuSocial's fully immersive environment. The platform will enable users to launch targeted digital campaigns combining marketing strategies with blockchain technology, facilitating engagement through digital tokens.
Nicholas Lyons, CEO of Arketyp Valu, and Dave Mehalick, CEO of COEPTIS, both expressed enthusiasm for the partnership, highlighting its potential to create a decentralized digital ecosystem that delivers value to users and businesses globally.
COEPTIS (Nasdaq: COEP) ha annunciato una partnership strategica tra il suo NexGenAI Affiliates Network e Arketyp Valu, uno sviluppatore all'interno dell'ecosistema del Progetto Verus. La collaborazione mira a integrare le soluzioni di marketing digitale di NexGenAI nella prossima ValuSocial platform, sfruttando la tecnologia blockchain di Verus Coin e i Public Blockchains as a Service (PBaaS).
Il Progetto Verus, che ha recentemente raggiunto una capitalizzazione di mercato superiore ai 500 milioni di dollari, fornirà le basi per l'ambiente completamente immersivo di ValuSocial. La piattaforma permetterà agli utenti di lanciare campagne digitali mirate che combinano strategie di marketing con la tecnologia blockchain, facilitando l'engagement attraverso token digitali.
Nicholas Lyons, CEO di Arketyp Valu, e Dave Mehalick, CEO di COEPTIS, hanno entrambi espresso entusiasmo per la partnership, sottolineando il suo potenziale nel creare un ecosistema digitale decentralizzato che offre valore agli utenti e alle aziende a livello globale.
COEPTIS (Nasdaq: COEP) ha anunciado una asociación estratégica entre su NexGenAI Affiliates Network y Arketyp Valu, un desarrollador dentro del ecosistema del Proyecto Verus. La colaboración tiene como objetivo integrar las soluciones de marketing digital de NexGenAI en la próxima ValuSocial platform, aprovechando la tecnología blockchain de Verus Coin y Public Blockchains as a Service (PBaaS).
El Proyecto Verus, que recientemente ha alcanzado una capitalización de mercado superior a los 500 millones de dólares, proporcionará la base para el entorno completamente inmersivo de ValuSocial. La plataforma permitirá a los usuarios lanzar campañas digitales dirigidas que combinan estrategias de marketing con tecnología blockchain, facilitando la interacción a través de tokens digitales.
Nicholas Lyons, CEO de Arketyp Valu, y Dave Mehalick, CEO de COEPTIS, expresaron entusiasmo por la asociación, resaltando su potencial para crear un ecosistema digital descentralizado que entregue valor a los usuarios y negocios a nivel global.
COEPTIS (Nasdaq: COEP)는 NexGenAI Affiliates Network와 Arketyp Valu 간의 전략적 파트너십을 발표했습니다. Arketyp Valu는 Verus 프로젝트 생태계 내의 개발자입니다. 이 협업은 NexGenAI의 디지털 마케팅 솔루션을 다가오는 ValuSocial platform에 통합하는 것을 목표로 하며, Verus Coin의 블록체인 기술과 Public Blockchains as a Service (PBaaS)를 활용합니다.
최근 5억 달러 이상의 시장 가치를 달성한 Verus 프로젝트는 ValuSocial의 완전 몰입형 환경을 위한 기초를 제공합니다. 이 플랫폼은 사용자들이 마케팅 전략과 블록체인 기술을 결합한 목표 지향적인 디지털 캠페인을 시작할 수 있도록 하여, 디지털 토큰을 통한 참여를 촉진합니다.
Arketyp Valu의 CEO인 Nicholas Lyons와 COEPTIS의 CEO인 Dave Mehalick는 이 파트너십에 대한 열정을 표명하며, 사용자와 비즈니스에 가치를 제공하는 분산형 디지털 생태계를 만드는 잠재력을 강조했습니다.
COEPTIS (Nasdaq: COEP) a annoncé un partenariat stratégique entre son NexGenAI Affiliates Network et Arketyp Valu, un développeur au sein de l'écosystème du Projet Verus. La collaboration vise à intégrer les solutions de marketing numérique de NexGenAI dans la prochaine ValuSocial platform, en tirant parti de la technologie blockchain de Verus Coin et des Public Blockchains as a Service (PBaaS).
Le Projet Verus, qui a récemment atteint une capitalisation boursière de plus de 500 millions de dollars, fournira les bases de l'environnement entièrement immersif de ValuSocial. La plateforme permettra aux utilisateurs de lancer des campagnes numériques ciblées combinant des stratégies marketing et la technologie blockchain, facilitant l'engagement via des jetons numériques.
Nicholas Lyons, PDG d'Arketyp Valu, et Dave Mehalick, PDG de COEPTIS, ont tous deux exprimé leur enthousiasme pour ce partenariat, soulignant son potentiel à créer un écosystème numérique décentralisé qui apporte de la valeur aux utilisateurs et aux entreprises à l'échelle mondiale.
COEPTIS (Nasdaq: COEP) hat eine strategische Partnerschaft zwischen seinem NexGenAI Affiliates Network und Arketyp Valu, einem Entwickler im Verus-Projekt-Ökosystem, bekannt gegeben. Die Zusammenarbeit zielt darauf ab, die digitalen Marketinglösungen von NexGenAI in die kommende ValuSocial platform zu integrieren und dabei die Blockchain-Technologie von Verus Coin und die Public Blockchains as a Service (PBaaS) zu nutzen.
Das Verus-Projekt, das kürzlich eine Marktkapitalisierung von über 500 Millionen Dollar erreicht hat, wird die Grundlage für die vollständig immersive Umgebung von ValuSocial bieten. Die Plattform ermöglicht es Nutzern, zielgerichtete digitale Kampagnen zu starten, die Marketingstrategien mit Blockchain-Technologie kombinieren und die Interaktion über digitale Token erleichtern.
Nicholas Lyons, CEO von Arketyp Valu, und Dave Mehalick, CEO von COEPTIS, äußerten beide ihre Begeisterung für die Partnerschaft und hoben ihr Potenzial hervor, ein dezentrales digitales Ökosystem zu schaffen, das den Nutzern und Unternehmen weltweit Wert bietet.
- Partnership with Verus Project, a blockchain platform with $500M market cap
- Integration of advanced digital marketing solutions into ValuSocial platform
- Access to scalable blockchain infrastructure through Verus' PBaaS
- None.
Insights
This strategic partnership marks COEPTIS' ambitious expansion into blockchain-enabled digital marketing, though it represents a significant pivot from their core biotechnology focus. The integration with Verus Network, which has achieved a
Technical Infrastructure & Market Potential:
- The partnership leverages Verus Coin's Public Blockchains as a Service (PBaaS), offering scalability advantages over traditional blockchain solutions
- ValuSocial's platform could potentially tap into the growing digital marketing sector, estimated at over
$400 billion globally - The integration of NexGenAI's marketing tools suggests capabilities in targeted advertising and user engagement, though specific technological differentiators remain unclear
Strategic Considerations & Risks:
- This venture represents a significant diversification from COEPTIS' biotechnology roots, raising questions about resource allocation and core competency alignment
- The blockchain marketing space is increasingly competitive, with established players like Basic Attention Token already operating in this sector
- Success will heavily depend on user adoption rates and the platform's ability to deliver measurable marketing ROI
- Regulatory compliance in both blockchain and digital marketing sectors could pose significant challenges
While the partnership shows promise in terms of technological infrastructure and market potential, investors should note that such ventures typically require substantial development time and resources before generating meaningful revenue. The lack of specific financial projections or implementation timelines suggests this is still in early stages, making it difficult to quantify the immediate impact on COEPTIS' valuation.
The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain Technology
WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu, a prominent developer within the open-source Verus Project, which has recently achieved a market capitalization exceeding
The innovative ValuSocial platform is set to transform the landscape of digital marketing by offering users a fully immersive environment where they can leverage NexGenAI's pioneering solutions. This integration will empower individuals and businesses to launch targeted digital campaigns that combine cutting-edge marketing strategies with the security and scalability of blockchain technology, enhancing engagement through seamless interaction and digital tokens.
“As CEO of Arketyp Valu, I am thrilled to lead this partnership and incorporate NexGenAI’s state-of-the-art tools into our upcoming ValuSocial platform,” stated Nicholas Lyons, CEO of Arketyp Valu. “This collaboration effectively merges the latest in digital marketing innovation with the reliable and scalable framework of the Verus network, heralding a new era of global digital engagement.”
Dave Mehalick, CEO of COEPTIS, expressed enthusiasm for the collaboration, saying, “Our tools are designed to empower businesses in the digital age, and their integration on the ValuSocial platform represents a transformative advancement. By combining our expertise with Arketyp Valu’s groundbreaking offerings, we are laying the groundwork for a decentralized, interconnected digital ecosystem that delivers value to users and businesses around the world.”
This partnership showcases the commitment of both COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu to drive innovation while redefining digital marketing capabilities. The ValuSocial platform, built on the secure foundations of the Verus Project, will deliver next-generation marketing solutions, allowing users to access advanced tools within a compliant and scalable blockchain environment.
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
About Arketyp Valu
Arketyp Valu is involved with the Verus project, which includes the development and promotion of Verus Coin. Verus Coin is a cryptocurrency that operates on the Verus blockchain, focusing on features such as privacy, security, and scalability.
The Verus project aims to create a decentralized ecosystem that empowers users while providing tools for developers to build applications that enhance the utility of the cryptocurrency. As a contributor and developer, Arketyp Valu plays a part in advancing the technology and applications associated with Verus Coin, helping to support its growth and adoption within the broader cryptocurrency community.
About NexGenAI Affiliates Network
NexGenAI Affiliates Network is a state-of-the-art AI-powered affiliate marketing platform designed to streamline marketing efforts through automation and advanced analytics. Owned by Coeptis Therapeutics Holdings Inc., NexGenAI Affiliates Network empowers individuals and businesses to optimize their affiliate campaigns and maximize revenue through AI-driven content distribution, automated email outreach, and social media integration. For more information on this partnership and how it can benefit businesses and affiliates, visit https://nexgenaiaffiliates.io/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
FAQ
What is the purpose of COEPTIS' partnership with Arketyp Valu?
What is the current market capitalization of the Verus Project that COEP is partnering with?
What features will the ValuSocial platform offer through COEP's NexGenAI integration?
How will COEP's partnership with Arketyp Valu benefit users?
